Today, blinatumomab, a BiTE that binds to CD3 on T cells and CD19 on B cells, is one of the few FDA-approved bispecific antibodies and is indicated for the treatment of relapsed or refractory B cell progenitor acute lymphoblastic leukemia (BCP-ALL). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.